Physician profile
Benjamin Bashinski
NPI 1649222712
$5,827.94
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,210 · 2020: $1,859 · 2021: $1,550 · 2022: $163 · 2023: $45.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $45.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $45.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $613.04 | 2019-2021 | |
| Abbvie INC. | $567.25 | 2020-2022 | |
| Emd Serono, INC. | $563.47 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $406.98 | 2019-2021 | |
| Eisai INC. | $392.58 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $353.73 | 2019-2021 | |
| Amgen INC. | $331.60 | 2019-2021 | |
| Biogen, INC. | $320.80 | 2019-2021 | |
| Allergan, INC. | $283.35 | 2019-2021 | |
| Genentech USA, INC. | $278.58 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $241.18 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $196.44 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $152.19 | 2020-2021 | |
| Sk Life Science, INC. | $120.80 | 2020-2021 | |
| Ucb, INC. | $93.40 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Bashinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.